Table 2.
Transthoracic echocardiography on unanesthetized MuRF1−/− and WT control mice after 2 wk of daily subcutaneous saline or dexamethasone treatment
|
Saline Treatment |
Dexamethasone Treatment
|
|||
|---|---|---|---|---|
| WT | MuRF1−/− | WT | MuRF1−/− | |
| n | 9 | 9 | 8 | 6 |
| Heart rate, beats/min | 581.3±22.5 | 614.9±12.1 | 585.8±15.7 | 596.8±13.1 |
| Anterior wall at diastole, mm | 1.20+0.02 | 1.26+0.02 | 1.03±0.02* | 1.26±0.04 |
| Posterior wall at diastole, mm | 1.18+0.04 | 1.19+0.01 | 0.97±0.01* | 1.18±0.01 |
| Anterior wall at systole, mm | 1.83+0.04 | 1.96+0.05 | 1.43±0.03 | 1.86±0.02 |
| Posterior wall at systole, mm | 1.70+0.04 | 1.58+0.03 | 1.44±0.03* | 1.67±0.03 |
| LVEDD | 2.8+0.4 | 3.4+0.3 | 3.0+0.1 | 3.2+0.1 |
| LVESD | 1.3+0.2 | 1.5+0.2 | 1.4+0.1 | 1.5+0.1 |
| LV mass/body weight, mg/g | 3.99+0.19 | 4.04+0.19 | 3.32±0.12* | 5.47±0.18* |
| LV mass/tibia length, mg/mm | 6.88+0.34 | 7.43+0.40 | 5.87±0.22* | 9.06±0.41* |
| Heart weight/body weight, mg/g | 5.20+0.28 | 5.74+0.25 | 4.18±0.07* | 6.01±0.25 |
| Fractional shortening, % | 54.5+1.0 | 55.0+0.9 | 52.8±1.8 | 54.8±0.8 |
| Ejection fraction, % | 86.5+0.90 | 86.5+0.7 | 84.7±1.5 | 86.4±0.6 |
Values are means ± SE; n, no. of mice/group. LVEDD, left ventricular (LV) end-diastolic dimension; LVESD, LV end-systolic dimension. LV mass was calculated as follows: (external LV diameter in diastole3 − LVEDD3) × 1.055. Fractional shortening was calculated as follows: (LVEDD − LVESD)/LVEDD × 100. The ejection fraction was calculated as follows: (end Simpson's diastolic volume − end Simpson's systolic volume)/end Simpson's diastolic volume × 100.
*
P < 0.05 vs. all other groups.